Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(19/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(19/week)
News
United States
(450/week)
Manufacturing
(348/week)
Technology
(352/week)
Energy
(230/week)
Other Manufacturing
(292/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Boston Biomedical, Inc.
Jul 01, 2020
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Apr 06, 2020
Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis
Mar 02, 2020
Boston Biomedical, Inc. Announces Investment by its Parent Company in MPM Oncology Innovations Fund
Mar 02, 2020
Boston Biomedical, Inc. Announces Investment by its Parent Company in MPM Oncology Innovations Fund
Dec 03, 2019
Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
Nov 08, 2019
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
Jul 01, 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Sep 13, 2018
Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment
Jun 01, 2018
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
May 17, 2018
Boston Biomedical, Inc. Announces Presentations for Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) to be Featured at ASCO 2018
Apr 25, 2018
Boston Biomedical Inc. Initiates Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)
Oct 16, 2017
Boston Biomedical, Inc. Appoints Edgar Braendle, M.D., Ph.D., as Head of Research and Development and Chief Medical Officer
Oct 10, 2017
Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer
Jul 10, 2017
Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome
Jun 30, 2017
Boston Biomedical Presents Data for Investigational Cancer Stemness Inhibitor Napabucasin in Metastatic Colorectal and Pancreatic Cancer at ESMO GI 2017
Jun 26, 2017
Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Jun 05, 2017
Boston Biomedical Presents Data for Investigational Stemness Inhibitor Amcasertib at ASCO 2017
Jun 03, 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017
Latest News
Mar 29, 2024
Mitsubishi Electric Announces Director Candidates
Mar 29, 2024
Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures
Mar 29, 2024
Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment
Mar 29, 2024
Mandalay Resources Corporation Announces Filing of Annual Information Form and Updated NI 43-101 Technical...
Mar 29, 2024
AUGUSTA GOLD ANNOUNCES LOAN INCREASE AND EXTENSION; APPOINTMENT OF TY MINNICK AS INTERIM CFO
Mar 29, 2024
Wheaton Precious Metals Provides Details of Annual and Special Meeting of Shareholders and Files Form 40-F
Mar 29, 2024
Hot Stamping Foils Market size to grow by USD 177.96 million from 2022 to 2027, The use of hot foil stamping...
Mar 29, 2024
Australia Plastic Packaging Market Analysis, Industry Growth Forecasts 2019-2029, Featuring Orora Packaging...
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events